BiotechTube

Methylprednisoloneacetate + Lidocaine

Phase 2Completed
0 views this week 0 watching💤 Quiet
Interest: 32/100
32
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Knee Joint Osteoarthrosis

Conditions

Knee Joint Osteoarthrosis, Hyperalgesia, Severe Movement Related Pain

Trial Timeline

Oct 1, 2014 → Mar 1, 2016

NCT ID
NCT02253966

About Methylprednisoloneacetate + Lidocaine

Methylprednisoloneacetate + Lidocaine is a phase 2 stage product being developed by Lundbeck for Knee Joint Osteoarthrosis. The current trial status is completed. This product is registered under clinical trial identifier NCT02253966. Target conditions include Knee Joint Osteoarthrosis, Hyperalgesia, Severe Movement Related Pain.

What happened to similar drugs?

11 of 20 similar drugs in Knee Joint Osteoarthrosis were approved

Approved (11) Terminated (0) Active (9)
✅NISEDr. Reddy's LaboratoriesApproved
✅Capsaicin Topical SolutionAstellas PharmaApproved
✅ImrecoxibJiangsu Hengrui MedicineApproved
✅celecoxibPfizerApproved
✅Ibuprofen + Placebo + CelecoxibPfizerApproved
✅Celecoxib + Naproxen + PlaceboPfizerApproved
✅Celecoxib + PlaceboPfizerApproved

Hype Score Breakdown

Clinical
12
Activity
8
Company
12
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT02253966Phase 2Completed

Competing Products

20 competing products in Knee Joint Osteoarthrosis

See all competitors
ProductCompanyStageHype Score
NISEDr. Reddy's LaboratoriesApproved
40
NISELATDr. Reddy's LaboratoriesPre-clinical
23
LY2828360 + PlaceboEli LillyPhase 2
35
UBX0101 or placeboUnity BiotechnologyPre-clinical
8
UBX0101Unity BiotechnologyPhase 1
19
UBX0101Unity BiotechnologyPhase 2
25
UBX0101Unity BiotechnologyPhase 1
19
YH23537 + Celecoxib + YH23537 placeboYuhanPhase 2
35
YM150 + WarfarinAstellas PharmaPhase 2
35
ASP7962 + Naproxen + PlaceboAstellas PharmaPhase 2
35
Capsaicin Topical SolutionAstellas PharmaApproved
43
CGS-200-1 + CGS-200-5 + CGS-200 VehicleAstellas PharmaPhase 2
35
MM-II dose I + MM-II dose II + MM-II dose III + Placebo + Placebo + PlaceboSun PharmaceuticalPhase 2
35
Duloxetine + PlaceboShionogiPhase 3
40
DuloxetineShionogiPhase 3
40
V120083 + Naproxen + PlaceboShionogiPhase 2
35
ONO-4474 + Placebo matching ONO-4474Ono PharmaceuticalPhase 2
27
Duloxetine + PlaceboEli LillyPhase 3
40
Duloxetine (DLX) + Placebo (PLA)Eli LillyPhase 3
40
Duloxetine + placeboEli LillyPhase 3
40